^
    Back
    Association details:
    Biomarker:CLDN18.2 expression
    Cancer:Gastric Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    givastomig (TJ-CD4B) (CLDN18.2 inhibitor, CD137 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    SITC 2023
    Title:

    792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer

    Published date:
    11/04/2023
    Excerpt:
    In a gastric cancer PDX model with moderate CLDN18.2 expression (25–50% of 2+), a triple-combination of givastomig, nivolumab and FOLFOX resulted in better tumor growth inhibition (TGI=40%), accompanied by an increase in tumor-infiltrating T cells, compared to nivolumab plus FOLFOX (TGI=8%).
    Secondary therapy:
    FOLFOX
    DOI:
    10.1136/jitc-2023-SITC2023.0792